AccessibilityHelp
MindMaze Therapeutics logo

MindMaze Therapeutics(OTC) RLFTF

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-92%
5 Year-99%
1 Year-95%
1 Month-1%
N/A
MindMaze Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.192026-10-23
MindMaze Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.4%USD 0.192026-10-16
1 month-1.28%USD 0.202026-09-23
3 month-2.9%USD 0.202026-07-24
Year to date-91.86%USD 2.392025-12-31
1 year-94.59%USD 3.592025-10-23
3 year-95.61%USD 4.422023-05-31
5 year-99.46%USD 35.722021-10-22
Since inception-91.91%USD 2.402025-12-16

MindMaze Therapeutics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 9.06M

Net Income (TTM)

-CHF 27.03M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Sep 26, 2024

RLFTF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MindMaze Therapeutics

MindMaze Therapeutics Holding S.A. is a biotechnology company focused on developing AI-powered neurotherapeutics and pharmacological treatments for brain disorders. The company aims to address neurological and neuropsychiatric conditions through advanced research, clinical development, and technology-driven solutions.

Products and Services
  • AI-driven neurotherapeutics for brain disorders
  • Pharmacological treatments targeting neurological conditions
  • Innovative technology solutions for clinical development
Growth Outlook
  • Recent partnerships enhance research capabilities and market reach
  • Expansion into new therapeutic areas expected to drive revenue growth
  • Increased investment in R&D to accelerate product development timelines
Financial Highlights
  • Q4 2025 reported revenue of -575,693 CHF, reflecting ongoing investment in R&D
  • Cash and cash equivalents at 9.48 million CHF as of Q4 2025
  • Net income for Q4 2025 was -5.43 million CHF, indicating significant operational costs
MindMaze Therapeutics Holding S.A. operates in a rapidly evolving sector, leveraging artificial intelligence to innovate treatment options for complex brain disorders. The company's commitment to research and development is evident in its substantial investments, which are crucial for long-term growth. Despite recent financial challenges, the strategic focus on partnerships and expanding therapeutic areas positions the company for potential future success. Investors may find interest in the company's unique approach to addressing significant unmet medical needs in the neurological space.
AI Generated • Oct 10, 2026

Industry

Biotechnology

Sector

Health Care

Employees

31

CEO

Alexandre Capet

Website

www.mindmazetherapeutics.com

Headquarters

Geneva, GE 1202, CH

RLFTF Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

N/A

Return on Capital

-26.19%

Return on Assets

N/A

Earnings Yield

N/A

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

CHF 4.79M

Operating Income

-CHF 29.41M

EBITDA

-CHF 25.16M

Operating Cash Flow

-CHF 9.82M

Capital Expenditure

-CHF 6.43M

Free Cash Flow

-CHF 16.23M

Cash & ST Invst.

CHF 9.48M

Total Debt

CHF 1.81M

MindMaze Therapeutics Performance Analysis

MindMaze Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 6,367,10575.3%
20232023-12-31CHF 6,713,3905.4%
20242024-12-31CHF 0N/A
20252025-12-31CHF 773,041N/A
MindMaze Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3087.8%
Q42024-12-31-51.1%
Q22025-06-30-55.9%
Q42025-12-31-147.3%
MindMaze Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF -5.0319.0%
20232023-12-31CHF -9.3084.8%
20242024-12-31CHF -0.00-100.0%
20252025-12-31CHF -0.58577600.0%
MindMaze Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3089.2%
Q42024-12-31-177.8%
Q22025-06-3064.0%
Q42025-12-3166.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

-CHF 575.69K

-119.1%

Gross Profit

-CHF 1.67M

+67.6%

Gross Margin

2.89%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

10

N/A

Net Income

-CHF 5.43M

+87.0%

EBITDA

-CHF 4.87M

+26.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CHF 9.48M

-34.9%

Total Debt

CHF 1.81M

-39.1%

Accounts Receivable

CHF 1.96M

+17.3%

Inventory

CHF 1.14M

+105.1%

Long Term Debt

CHF 1.18M

-43.8%

Short Term Debt

CHF 629.30K

-27.7%

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-CHF 9.37M

-31.4%

Operating Cash Flow

-CHF 3.14M

+55.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PSYBFPsyBio Therapeutics Corp
$0.00+0.00%
HBPCFHelix BioPharma Corp.
$0.77+0.00%
INNMFAmplia Therapeutics Limited
$0.06+3.77%
OTLCOncotelic Therapeutics, Inc.
$0.02+24.22%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About RLFTF

What is the current price of MindMaze Therapeutics?

MindMaze Therapeutics is trading at N/A per share.

What is the 52-week range for MindMaze Therapeutics?

Over the past 52 weeks, MindMaze Therapeutics has traded between N/A and N/A.

How much debt does MindMaze Therapeutics have?

As of the most recent reporting period, MindMaze Therapeutics reported total debt of CHF 2.28M.

How much cash does MindMaze Therapeutics have on hand?

MindMaze Therapeutics reported CHF 11.96M in cash and cash equivalents in its most recent financial results.

What is MindMaze Therapeutics’s dividend yield?

MindMaze Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services